Esma Saâda-Bouzid
YOU?
Author Swipe
View article: Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial Open
View article: A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM) Open
The I2 substudy failed to demonstrate an activity of D + M in heavily pretreated patients with SCCHN previously exposed to anti-PD(L)1. No benefit was seen in PFS and OS.
View article: Hpv Circulating Tumor DNA to Monitor Response to Pembrolizumab and Vorinostat Combination in Patients with Advanced Hpv-Related Squamous Cell Carcinomas
Hpv Circulating Tumor DNA to Monitor Response to Pembrolizumab and Vorinostat Combination in Patients with Advanced Hpv-Related Squamous Cell Carcinomas Open
View article: Liposarcomas: Natural History of 11132 Patients from the NETSARC Nationwide Registry
Liposarcomas: Natural History of 11132 Patients from the NETSARC Nationwide Registry Open
View article: Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study Open
Background The MOVIE phase I/II trial ( NCT03518606 ) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recu…
View article: Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO Open
Though the primary endpoint of OSAD93 was not met, this pre-operative doxorubicin-free regimen led to excellent long-term survival with limited toxicity in localized osteosarcoma.
View article: First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC Open
NCT04272203.
View article: Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study Open
Background Novel treatments are needed for patients with advanced, triple‐negative breast cancer (TNBC) that progresses or recurs after first‐line treatment with chemotherapy. The authors report results from the TNBC cohort of the multicoh…
View article: Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial Open
For the French translation of the abstract see Supplementary Materials section.
View article: Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial Open
For the French translation of the abstract see Supplementary Materials section.
View article: Improved nationwide survival of sarcoma patients with a network of reference centers
Improved nationwide survival of sarcoma patients with a network of reference centers Open
View article: Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity Open
There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of afatinib, a pan-HER tyrosine kinase in…
View article: Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years
Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years Open
Although sharing close molecular alterations, SEF and LGFMS have a different natural history, clinical presentation and outcome, with a higher risk of metastatic relapse in SEF. Survival after relapse is longer than with other sarcomas, an…
View article: Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study Open
View article: Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacy
Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacy Open
There is no strong and reliable predictive biomarker in head and neck squamous cell carcinoma (HNSCC) for EGFR inhibitors. We aimed to identify predictive and pharmacodynamic biomarkers of efficacy of afatinib, a pan-HER tyrosine kinase in…
View article: Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years Open
View article: Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study Open
View article: Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study Open
This study failed to show any signal of benefit for regorafenib in patients with advanced/metastatic recurrent chordoma.
View article: Enteral Nutrition during Radiotherapy for Oropharyngeal Cancers: Prevalence and Prognostic Factors Based on HPV Status (A GETTEC Study)
Enteral Nutrition during Radiotherapy for Oropharyngeal Cancers: Prevalence and Prognostic Factors Based on HPV Status (A GETTEC Study) Open
Nutritional support during radiotherapy is crucial to tolerating and completing oropharyngeal squamous cell carcinoma (OPSCC) treatment. The impact of HPV status on nutritional support is debated. The objective was to evaluate the rate of …
View article: Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas Open
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Missense mutations in the polymerase epsilon (POLE) gene have been reported to generate proofreading defects resulting in an ultramutated genome and to sensitize tumors to checkpoint blockade immunotherapy. However, many POLE…
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Missense mutations in the polymerase epsilon (POLE) gene have been reported to generate proofreading defects resulting in an ultramutated genome and to sensitize tumors to checkpoint blockade immunotherapy. However, many POLE…
View article: Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
View article: Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon Open
Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon